Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Conditions

• Obesity

Interventions

• DRUG: S-2367 Placebo
• DRUG: S-2367 1600 mg q.d. 54 Weeks
• DRUG: S-2367 1600 mg q.d. 60 weeks
• OTHER: LCD (low calorie diet)
• OTHER: RCD (reduced calorie diet)

Sponsor

Shionogi